173 related articles for article (PubMed ID: 36382714)
21. The A31P missense mutation in cardiac myosin binding protein C alters protein structure but does not cause haploinsufficiency.
van Dijk SJ; Bezold Kooiker K; Mazzalupo S; Yang Y; Kostyukova AS; Mustacich DJ; Hoye ER; Stern JA; Kittleson MD; Harris SP
Arch Biochem Biophys; 2016 Jul; 601():133-40. PubMed ID: 26777460
[TBL] [Abstract][Full Text] [Related]
22. Genetics of feline hypertrophic cardiomyopathy.
Gil-Ortuño C; Sebastián-Marcos P; Sabater-Molina M; Nicolas-Rocamora E; Gimeno-Blanes JR; Fernández Del Palacio MJ
Clin Genet; 2020 Sep; 98(3):203-214. PubMed ID: 32215921
[TBL] [Abstract][Full Text] [Related]
23. Effects of ivabradine on heart rate and left ventricular function in healthy cats and cats with hypertrophic cardiomyopathy.
Riesen SC; Schober KE; Smith DN; Otoni CC; Li X; Bonagura JD
Am J Vet Res; 2012 Feb; 73(2):202-12. PubMed ID: 22280379
[TBL] [Abstract][Full Text] [Related]
24. A cardiac myosin binding protein C mutation in the Maine Coon cat with familial hypertrophic cardiomyopathy.
Meurs KM; Sanchez X; David RM; Bowles NE; Towbin JA; Reiser PJ; Kittleson JA; Munro MJ; Dryburgh K; Macdonald KA; Kittleson MD
Hum Mol Genet; 2005 Dec; 14(23):3587-93. PubMed ID: 16236761
[TBL] [Abstract][Full Text] [Related]
25. Contractile dysfunction irrespective of the mutant protein in human hypertrophic cardiomyopathy with normal systolic function.
van Dijk SJ; Paalberends ER; Najafi A; Michels M; Sadayappan S; Carrier L; Boontje NM; Kuster DW; van Slegtenhorst M; Dooijes D; dos Remedios C; ten Cate FJ; Stienen GJ; van der Velden J
Circ Heart Fail; 2012 Jan; 5(1):36-46. PubMed ID: 22178992
[TBL] [Abstract][Full Text] [Related]
26. Naturally Occurring Biventricular Noncompaction in an Adult Domestic Cat.
Kittleson MD; Fox PR; Basso C; Thiene G
J Vet Intern Med; 2017 Mar; 31(2):527-531. PubMed ID: 28158907
[TBL] [Abstract][Full Text] [Related]
27. The Feline Cardiomyopathies: 2. Hypertrophic cardiomyopathy.
Kittleson MD; Côté E
J Feline Med Surg; 2021 Nov; 23(11):1028-1051. PubMed ID: 34693811
[TBL] [Abstract][Full Text] [Related]
28. Precision medicine validation: identifying the
Ontiveros ES; Ueda Y; Harris SP; Stern JA;
J Feline Med Surg; 2019 Dec; 21(12):1086-1093. PubMed ID: 30558461
[TBL] [Abstract][Full Text] [Related]
29. Hypertrophic cardiomyopathy-linked variants of cardiac myosin-binding protein C3 display altered molecular properties and actin interaction.
Da'as SI; Fakhro K; Thanassoulas A; Krishnamoorthy N; Saleh A; Calver BL; Safieh-Garabedian B; Toft E; Nounesis G; Lai FA; Nomikos M
Biochem J; 2018 Dec; 475(24):3933-3948. PubMed ID: 30446606
[TBL] [Abstract][Full Text] [Related]
30. Assessment of left ventricular systolic function by strain imaging echocardiography in various stages of feline hypertrophic cardiomyopathy.
Wess G; Sarkar R; Hartmann K
J Vet Intern Med; 2010; 24(6):1375-82. PubMed ID: 20738767
[TBL] [Abstract][Full Text] [Related]
31. Association of the myosin binding protein C3 mutation (MYBPC3 R820W) with cardiac death in a survey of 236 Ragdoll cats.
Borgeat K; Casamian-Sorrosal D; Helps C; Luis Fuentes V; Connolly DJ
J Vet Cardiol; 2014 Jun; 16(2):73-80. PubMed ID: 24906243
[TBL] [Abstract][Full Text] [Related]
32. Speckle tracking echocardiography in cats with preclinical hypertrophic cardiomyopathy.
Spalla I; Boswood A; Connolly DJ; Luis Fuentes V
J Vet Intern Med; 2019 May; 33(3):1232-1241. PubMed ID: 30993757
[TBL] [Abstract][Full Text] [Related]
33. Contractile abnormalities and altered drug response in engineered heart tissue from Mybpc3-targeted knock-in mice.
Stöhr A; Friedrich FW; Flenner F; Geertz B; Eder A; Schaaf S; Hirt MN; Uebeler J; Schlossarek S; Carrier L; Hansen A; Eschenhagen T
J Mol Cell Cardiol; 2013 Oct; 63():189-98. PubMed ID: 23896226
[TBL] [Abstract][Full Text] [Related]
34. A hypertrophic cardiomyopathy-associated MYBPC3 mutation common in populations of South Asian descent causes contractile dysfunction.
Kuster DW; Govindan S; Springer TI; Martin JL; Finley NL; Sadayappan S
J Biol Chem; 2015 Feb; 290(9):5855-67. PubMed ID: 25583989
[TBL] [Abstract][Full Text] [Related]
35. Aficamten: A Breakthrough Therapy for Symptomatic Obstructive Hypertrophic Cardiomyopathy.
Sebastian SA; Padda I; Lehr EJ; Johal G
Am J Cardiovasc Drugs; 2023 Sep; 23(5):519-532. PubMed ID: 37526885
[TBL] [Abstract][Full Text] [Related]
36. Heat shock proteins and small nucleolar RNAs are dysregulated in a Drosophila model for feline hypertrophic cardiomyopathy.
Tallo CA; Duncan LH; Yamamoto AH; Slaydon JD; Arya GH; Turlapati L; Mackay TFC; Carbone MA
G3 (Bethesda); 2021 Jan; 11(1):. PubMed ID: 33561224
[TBL] [Abstract][Full Text] [Related]
37. Prognostic indicators in cats with hypertrophic cardiomyopathy.
Payne JR; Borgeat K; Connolly DJ; Boswood A; Dennis S; Wagner T; Menaut P; Maerz I; Evans D; Simons VE; Brodbelt DC; Luis Fuentes V
J Vet Intern Med; 2013; 27(6):1427-36. PubMed ID: 24134821
[TBL] [Abstract][Full Text] [Related]
38. Cardiac Effects of a Single Dose of Pimobendan in Cats With Hypertrophic Cardiomyopathy; A Randomized, Placebo-Controlled, Crossover Study.
Oldach MS; Ueda Y; Ontiveros ES; Fousse SL; Harris SP; Stern JA
Front Vet Sci; 2019; 6():15. PubMed ID: 30778391
[No Abstract] [Full Text] [Related]
39. Diltiazem prevents stress-induced contractile deficits in cardiomyocytes, but does not reverse the cardiomyopathy phenotype in Mybpc3-knock-in mice.
Flenner F; Geertz B; Reischmann-Düsener S; Weinberger F; Eschenhagen T; Carrier L; Friedrich FW
J Physiol; 2017 Jun; 595(12):3987-3999. PubMed ID: 28090637
[TBL] [Abstract][Full Text] [Related]
40. MYBPC3 mutations are associated with a reduced super-relaxed state in patients with hypertrophic cardiomyopathy.
McNamara JW; Li A; Lal S; Bos JM; Harris SP; van der Velden J; Ackerman MJ; Cooke R; Dos Remedios CG
PLoS One; 2017; 12(6):e0180064. PubMed ID: 28658286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
